Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

doi:10.1200/JCO.20.00948

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Dec 2020

Kater Arnon P, Wu Jenny Qun, Kipps Thomas, Eichhorst Barbara, Hillmen Peter, D'Rozario James, Assouline Sarit, Owen Carolyn, Robak Tadeusz, de la Serna Javier, Jaeger Ulrich, Cartron Guillaume, Montillo Marco, Dubois Julie, Eldering Eric, Mellink Clemens, Van Der Kevie-Kersemaekers Anne-Marie, Kim Su Young, Chyla Brenda, Punnoose Elizabeth, Bolen Christopher R, Assaf Zoe June, Jiang Yanwen, Wang Jue, Lefebure Marcus, Boyer Michelle, Humphrey Kathryn, Seymour John F

Abstract excerpt

PURPOSE: In previous analyses of the MURANO study, fixed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine plus rituximab (BR) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL). At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, and the predictive value of molecular and genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Exportin 1 Protein

Share to Karyopherins

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Progression-Free Survival

Share to Receptor, Notch1

Share to Receptors, Cytoplasmic and Nuclear

Share to Rituximab

Source

Open in PubMed Open full text

Identifiers

PMID: 32986498
DOI: 10.1200/JCO.20.00948
PMCID: PMC7768340

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study.PMID 32986498Read ↗

Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma.Semantic proximity Read ↗

Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.Semantic proximity Read ↗

Venetoclax consolidation in high-risk CLL treated with ibrutinib for ≥1 year achieves a high rate of undetectable MRDSemantic proximity Read ↗

Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.Semantic proximity Read ↗

Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived.Semantic proximity Read ↗

Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapySemantic proximity Read ↗

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.Semantic proximity Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients.Semantic proximity Read ↗

Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.